BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 29312332)

  • 1. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
    Wirth TC; Kühnel F
    Front Immunol; 2017; 8():1848. PubMed ID: 29312332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
    Martin SD; Coukos G; Holt RA; Nelson BH
    Ann Oncol; 2015 Dec; 26(12):2367-74. PubMed ID: 26371284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy.
    Verdon DJ; Jenkins MR
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting neoantigens for cancer immunotherapy.
    Zhao X; Pan X; Wang Y; Zhang Y
    Biomark Res; 2021 Jul; 9(1):61. PubMed ID: 34321091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoantigens and their clinical applications in human gastrointestinal cancers.
    Eshkiki ZS; Agah S; Tabaeian SP; Sedaghat M; Dana F; Talebi A; Akbari A
    World J Surg Oncol; 2022 Sep; 20(1):321. PubMed ID: 36171610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
    Okada M; Shimizu K; Fujii SI
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigens: promising targets for cancer therapy.
    Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
    Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Neoantigens in Cancer Immunotherapy.
    Zhu Y; Liu J
    Front Oncol; 2021; 11():682325. PubMed ID: 34513673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
    Bethune MT; Joglekar AV
    Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in Neoantigen Targeted Cancer Immunotherapies.
    Han XJ; Ma XL; Yang L; Wei YQ; Peng Y; Wei XW
    Front Cell Dev Biol; 2020; 8():728. PubMed ID: 32850843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
    Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
    Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
    Borden ES; Buetow KH; Wilson MA; Hastings KT
    Front Oncol; 2022; 12():836821. PubMed ID: 35311072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proteogenomic approach to target neoantigens in solid tumors.
    Verma A; Halder A; Marathe S; Purwar R; Srivastava S
    Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
    Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying neoantigens for use in immunotherapy.
    Hutchison S; Pritchard AL
    Mamm Genome; 2018 Dec; 29(11-12):714-730. PubMed ID: 30167844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
    Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
    Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.
    Efremova M; Finotello F; Rieder D; Trajanoski Z
    Front Immunol; 2017; 8():1679. PubMed ID: 29234329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.